Welcome to our dedicated page for OSR Health SEC filings (Ticker: OSRHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OSR Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OSR Health's regulatory disclosures and financial reporting.
OSR Holdings, Inc. reported that it entered into an Asset Purchase Agreement with its indirect subsidiary Vaximm AG on May 27, 2026. The deal is a related party transaction and is designed to transfer outright ownership of intellectual property related to Vaximm’s programs from Vaximm to OSR Holdings.
This transfer aligns with a previously executed Global Exclusive License Agreement among OSR Holdings, Vaximm and BCM Europe AG covering VXM01, an oral DNA-based cancer immunotherapy. After the transfer, OSR Holdings will directly hold the underlying intellectual property and be the direct beneficiary of any future milestone and royalty payments arising from the license. The agreement includes customary representations, covenants, indemnification and confidentiality terms and is governed by Swiss law.
OSR Holdings, Inc. is calling an annual meeting on June 18, 2026 to vote on five proposals. Stockholders will elect seven directors, ratify the 2026 independent auditor, and cast an advisory say-on-pay vote on 2025 executive compensation.
The company also seeks approval to amend its 2025 Omnibus Incentive Plan, raising the share reserve from 6,300,000 to 8,000,000 shares, and to change its legal name to OSR Health, Inc.. Holders of 35,104,695 shares of common stock as of May 6, 2026 are entitled to one vote per share. The board unanimously recommends voting “FOR” all proposals.
OSR Holdings, Inc. filed an amended current report to add an independent fairness opinion on its related-party Global Exclusive License Agreement for cancer immunotherapy asset VXM01 with BCM Europe. The opinion concludes that up to $815 million in clinical, regulatory, and commercial milestones plus royalties are financially fair to OSR, Vaximm, and unaffiliated shareholders, based on a Monte Carlo median standalone asset value of about $93.4 million and a 40/60 licensor–licensee value split. The structure includes a 15% preferred return on any milestone shortfall recovered from downstream royalties, an option for OSR to issue up to $15 million of stock at $10.00 per share, and full pass-through of royalties after recovery. A contemplated blockchain-based TAC token royalty mechanism is explicitly excluded from the fairness conclusion.
OSR Holdings, Inc. entered a definitive global exclusive license agreement with its largest shareholder, BCM Europe AG, for VXM01, a Phase 3-ready oral immunotherapy targeting VEGFR-2. The structure includes potential milestone obligations of up to $815 million tied to VXM01’s development and commercialization.
To secure these obligations, BCM Europe and affiliates signed a Pledge Agreement, pledging their entire unencumbered OSR Holdings stake, representing about 29.7% of shares as of signing, as collateral. The deal also grants OSR Holdings a put option to require BCM Europe to buy up to $15 million of common stock at $10.00 per share, exercisable no earlier than six months after the agreement takes effect. The transaction is a related party deal and was approved by the Board, including independent directors, after an independent fairness opinion.
joint protein central, inc. filed a Schedule 13G reporting beneficial ownership of 2,603,759 shares of OSR Holdings, Inc. common stock, representing 7.9% of the class. The filing shows sole voting power over 2,603,759 shares and no dispositive power. The form is signed by Senyon Choe, Director on 04/22/2026.
OSR Holdings, Inc. appointed Yeiseok Kim as Chief Operating Officer, effective April 16, 2026. The Board approved his appointment on March 26, 2026, and an amended employment agreement provides for increased annual compensation.
Kim, age 36, previously served as a Senior Analyst at OSR Holdings Co., Ltd. from 2020 to 2025, supporting cross-border healthcare investments and pharmaceutical licensing. He holds a BA in Environmental Science from Seoul National University and an MS in Medicine from Jeonbuk National University, along with a Korean medical license obtained in 2019.
The company notes there are no special arrangements or understandings behind his appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
OSR Holdings, Inc. executive Kim Yeiseok, the Chief Operating Officer, filed an initial Form 3 reporting beneficial ownership of 24,699 shares of the company’s Common Stock. These shares are reported as held directly, and the filing does not show any recent purchase or sale transactions.
OSR Holdings, Inc. filed an amended current report to correct an exhibit attached to a prior disclosure. The amendment replaces Exhibit 10.1 with a corrected version of the Global License Agreement for VXM01, dated March 23, 2026, among Vaximm AG, OSR Holdings, Inc. and BCM Europe AG. The update is described as fixing clerical errors, including the stated per share price, and does not change any other information contained in the original report.
OSR Holdings, Inc. entered into a binding term sheet with BCM Europe AG for a revised global exclusive license of VXM01, with OSR Holdings added as a direct counterparty and primary recipient of economics.
Upon a definitive license agreement, Vaximm AG will grant BCME an exclusive, worldwide, sublicensable license to develop and commercialize VXM01. BCME will be responsible for up to $815.0 million in milestone payments payable directly to OSR Holdings, while OSR Holdings will provide Vaximm with a development financing facility of up to $30.0 million. Closing of a definitive agreement is subject to due diligence, board approvals, and an independent fairness opinion.